2026-05-20T23:31:59Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/186042024-02-27T14:58:11Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16969col_20.500.12105_16973col_20.500.12105_16983col_20.500.12105_16984
Repisalud author Ocaña, Alberto author Chacón, Jose Ignacio author Calvo, Lourdes author Antón, Antonio author Mansutti, Mauro author Albanell, Joan author Martínez, María Teresa author Lahuerta, Ainhara author Bisagni, Giancarlo author Bermejo, Begoña author Semiglazov, Vladimir author Thill, Marc author Chan, Arlene author Morales, Serafin author Herranz, Jesús author Tusquets, Ignacio author Chiesa, Massimo author Caballero, Rosalía author Valagussa, Pinuccia author Bianchini, Giampaolo author Alba, Emilio author Gianni, Luca 2024-02-27T14:58:11Z 2024-02-27T14:58:11Z 2022-02-11 10.3389/fonc.2021.827625 2234-943X Frontiers in oncology http://hdl.handle.net/10668/20678 35223459 http://hdl.handle.net/20.500.12105/18604 Derived neutrophil-to-lymphocyte ratio (dNLR) is a biomarker associated with clinical outcome in breast cancer (BC). We analyzed the association of dNLR with pathological complete response (pCR) in triple-negative BC (TNBC) patients receiving neoadjuvant chemotherapy (CT). This is a retrospective analysis of two randomized studies involving early stage/locally advanced TNBC patients receiving anthracycline/taxane-based CT+/-carboplatin (GEICAM/2006-03) or nab-paclitaxel/paclitaxel followed by anthracycline regimen (ETNA). dNLR was calculated as the ratio of neutrophils to the difference between total leukocytes and neutrophils in peripheral blood before CT (baseline) and at the end of treatment (EOT). Logistic regression analyses were used to explore dNLR association with pCR. In total, 308 TNBC patients were analyzed, 216 from ETNA and 92 from GEICAM/2006-03. Baseline median dNLR was 1.61 (interquartile range (IQR): 1.25-2.04) and at EOT 1.53 (IQR: 0.96-2.22). Baseline dNLR showed positive correlation with increased tumor size (p-value = 1e-04). High baseline dNLR, as continuous variable or using median cutoff, was associated with lower likelihood of pCR in univariate analysis. High EOT dNLR as continuous variable or using quartiles was also associated with lower pCR rate in uni- and multivariate analyses. High baseline and EOT dNLR correlates with lower benefit from neoadjuvant CT in TNBC. eng DNLR PCR breast cancer immunology neoadjuvant chemotherapy Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. research article